Exploring the Risk-Knowledge Infinity Cycle (RKI Cycle) across the Product Lifecycle
Marty Lipa
Case studies demonstrating the link between knowledge and risk in technology transfer and commercial manufacture
Since the publishing of ICH Q10, Quality Risk Management (QRM) and Knowledge Management (KM) have been positioned as dual enablers to an effective Pharmaceutical Quality System. While there is broad agreement QRM and KM are highly interdependent in principle, there is recognition they are not well integrated in practice, and better integration is an opportunity to better manage risk and thus, increase patient protection.
A framework, the Risk-Knowledge Infinity Cycle (RKI Cycle), has been developed as a result of a research study carried out in conjunction with TU Dublin, to better integrate QRM and Knowledge Management which can be applied across the entire product lifecycle. Details of the framework will be explored in an upcoming ISPE webinar, and application of the Risk-Knowledge Infinity Cycle Cycle to the Commercial Manufacturing and Technology Transfer lifecycle phases will be illustrated through multiple short case studies, including examples to demonstrate the benefits of effective tacit knowledge transfer. In addition, a re-imagined PQS foundation will presented, enabled by QRM and Knowledge Management as intentionally connected and synergistic practices, as a means to reduce risk and ultimately benefit patients.
Martin (Marty) Lipa has over 25 years’ industry experience and 12 years’ experience in Knowledge Management. Lipa has published several industry specific works and is...
Following an unprecedented two years in which the pharmaceutical industry has faced numerous challenges posed by the global pandemic, pharmaceutical manufacturing has had to react and respond to meet the rapidly changing requirements and timelines. This has necessitated a radical rethink in how we...
Continuous manufacturing (CM) is gaining traction in pharmaceutical manufacturing. The purpose of this post is to highlight some of the differences between small molecule Drug Substance (DS) and Drug Product (DP) continuous manufacturing (CM), which may be helpful in considering the development and...
Gaelle Saint-Louis is the Women in Pharma® (WIP) Chair of the ISPE San Diego Chapter. She began her involvement with ISPE as the Young Professional (now Emerging Leaders) Chair for the Greater Los Angeles Chapter in 2019. After relocating to San Diego, she took on a leadership role within the...